Loading...
XJPX
4553
Market cap1.06bUSD
Dec 05, Last price  
3,340.00JPY
1D
2.61%
1Q
10.23%
Jan 2017
118.78%
IPO
317.50%
Name

Towa Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XJPX:4553 chart
P/E
8.66
P/S
0.63
EPS
385.68
Div Yield, %
1.80%
Shrs. gr., 5y
-1.53%
Rev. gr., 5y
18.65%
Revenues
259.59b
+13.89%
24,193,839,00029,235,198,00031,495,472,00035,966,812,00039,043,520,00046,145,000,00048,719,000,00055,241,000,00061,351,000,00071,470,000,00082,115,000,00084,949,000,00093,430,000,000105,104,000,000110,384,000,000154,900,000,000165,615,000,000208,859,000,000227,934,000,000259,594,000,000
Net income
18.99b
+17.39%
1,012,356,0002,598,101,0002,692,849,0003,777,129,0004,601,958,0005,846,000,0005,737,000,0006,201,000,0005,992,000,00011,118,000,0007,684,000,0005,576,000,0006,495,000,00013,475,000,00014,503,000,00013,958,000,00015,914,000,0002,201,000,00016,173,000,00018,986,000,000
CFO
23.40b
+184.96%
1,039,115,0002,648,617,0003,714,329,0004,471,651,0006,557,847,0005,739,000,0003,379,000,0008,645,000,0008,144,000,0008,037,000,0003,732,000,00010,195,000,00019,230,000,00019,002,000,00019,164,000,00012,008,000,00022,129,000,0002,544,000,0008,212,000,00023,401,000,000
Dividend
Mar 30, 202640 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
URL
https://www.towayakuhin.co.jp/
IPO date
Apr 05, 2004
Employees
4,298
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT